Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) CEO Margaret Tooth sold 2,294 shares of Trupanion stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $31.39, for a total value of $72,008.66. Following the transaction, the chief executive officer now owns 118,784 shares in the company, valued at $3,728,629.76. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Trupanion Price Performance
NASDAQ:TRUP opened at $32.66 on Friday. The company has a quick ratio of 1.66, a current ratio of 1.71 and a debt-to-equity ratio of 0.39. The business’s 50-day simple moving average is $44.46 and its two-hundred day simple moving average is $47.54. The stock has a market cap of $1.38 billion, a PE ratio of -142.00, a P/E/G ratio of 6.02 and a beta of 1.60. Trupanion, Inc. has a 52 week low of $19.69 and a 52 week high of $57.90.
Trupanion (NASDAQ:TRUP – Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The financial services provider reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The business had revenue of $337.31 million for the quarter, compared to the consensus estimate of $335.41 million. Trupanion had a negative net margin of 0.75% and a negative return on equity of 3.08%. As a group, analysts forecast that Trupanion, Inc. will post 0.13 EPS for the current fiscal year.
Institutional Investors Weigh In On Trupanion
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. Stifel Nicolaus lowered their target price on Trupanion from $44.00 to $41.00 and set a “hold” rating on the stock in a research report on Thursday, February 20th. Piper Sandler lowered their target price on Trupanion from $57.00 to $52.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Trupanion presently has an average rating of “Moderate Buy” and a consensus price target of $46.60.
View Our Latest Report on Trupanion
Trupanion Company Profile
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
See Also
- Five stocks we like better than Trupanion
- 10 Best Airline Stocks to Buy
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- What is the NASDAQ Stock Exchange?
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.